Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation

• Published in: Heart rhythm Vol. 13; no. 7; pp. 1410 - 1417
• Main Authors: Huang, Henry D., MD, Waks, Jonathan W., MD, Steinhaus, Daniel A., MD, Zimetbaum, Peter, MD, FHRS
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-07-2016
• Subjects: Aged; Anti-Arrhythmia Agents - administration & dosage; Anti-Arrhythmia Agents - adverse effects; Atrial fibrillation; Atrial Fibrillation - diagnosis; Atrial Fibrillation - drug therapy; Atrial Fibrillation - physiopathology; Cardiovascular; Cardioversion; Cohort Studies; Dofetilide; Electric Countershock - methods; Electric Countershock - statistics & numerical data; Electrocardiography - drug effects; Electrocardiography - methods; Female; Heart Conduction System - drug effects; Heart Conduction System - physiopathology; Humans; Male; Massachusetts; Middle Aged; Phenethylamines - administration & dosage; Phenethylamines - adverse effects; QT interval, Antiarrhythmic drug; Recurrence; Retrospective Studies; Sulfonamides - administration & dosage; Sulfonamides - adverse effects; QT interval, Antiarrhythmic drug; Cardioversion; Dofetilide; Atrial fibrillation
• ISSN: 1547-5271; 1556-3871
• DOI: 10.1016/j.hrthm.2016.02.016

Background Dofetilide is a class III antiarrhythmic drug approved for the treatment of atrial fibrillation (AF). Dofetilide-induced corrected QT (QTc) interval prolongation is a surrogate for the degree of drug effect, but the relationships between drug-induced QTc interval prolongation, pharmacological cardioversion (PCV), and freedom from recurrent AF are unclear. Objective The purpose of this study was to assess associations between QTc interval change during dofetilide initiation and PCV and long-term AF recurrence. Methods We performed retrospective analyses of a prospective cohort of patients with AF admitted for dofetilide initiation between 2001 and 2014. Clinical characteristics and electrocardiographic variables were assessed. We evaluated outcomes of successful PCV in patients with persistent AF and time to recurrence of AF in patients with paroxysmal and persistent AF. Results During the study, 243 patients with persistent AF and 176 patients with paroxysmal AF initiated dofetilide. PCV occurred in 93/243 (41.7%) patients with persistent AF. After multivariable adjustment, QTc interval change was associated with PCV (adjusted odds ratio 1.21; P = .003 per 10-ms QTc increase). Inhospital QTc interval change was associated with long-term freedom from AF in patients with persistent AF (adjusted hazard ratio 0.92; P = .011 at 4 years per 10-ms QTc increase), but not in patients with paroxysmal AF. In patients with persistent AF, PCV was also associated with long-term freedom from recurrent AF (adjusted hazard ratio 0.62; P = .009 at 4 years). Conclusion The magnitude of QTc interval prolongation during dofetilide initiation is an independent predictor of successful PCV and long-term freedom from arrhythmia in patients with persistent AF. QTc interval change had no association with AF recurrence in patients with paroxysmal AF, suggesting that different mechanisms of arrhythmogenesis may be operant in different AF types.